N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Acute Kidney Impairment Due to Contrast in Patients with Stage I-III Chronic Kidney Disease Undergoing Cardiac Catheterization – Indonesian Perspective

Jonny Jonny; Thomas Rikl; Ananda Rossi; Bhimo Aji Hernowo

Authors

Jonny Jonny Universitas Prima Indonesia, Medan, Indonesia Author
Thomas Rikl Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia Author
Ananda Rossi Rumah Sakit Pusat Angkatan Darat Gatot Soebroto, Jakarta, Indonesia Author
Bhimo Aji Hernowo Universitas Prima Indonesia, Medan, Indonesia Author

Keywords:

Brain Natriuretic Peptide, Contrast-Induced Acute Kidney Disorders, Cardiac Catheterization, Coronary Angiography, Chronic Kidney Disease

Abstract

On Process

Downloads

Download data is not yet available.

Author Biographies

Jonny Jonny, Universitas Prima Indonesia, Medan, Indonesia

Faculty of Medicine

Department of Internal Medicine, Gatot Soebroto Army Central Hospital, Jakarta, Indonesia

Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Indonesia

Faculty of Military Medicine, Indonesia Defense University, Bogor, Indonesia
Thomas Rikl, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia

Department of Cardiology and Vascular Medicine
Ananda Rossi, Rumah Sakit Pusat Angkatan Darat Gatot Soebroto, Jakarta, Indonesia

Direktorat Pengembangan dan Riset
Bhimo Aji Hernowo, Universitas Prima Indonesia, Medan, Indonesia

Faculty of Medicine

References

1. Azzalini L, Kalra S. Contrast-Induced Acute Kidney Injury—Definitions, Epidemiology, and Implications. Interv Cardiol Clin. 2020;9(3):299–309.

2. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84.

3. Schilcher G, Ribitsch W, Otto R, Portugaller RH, Quehenberger F, Truschnig-Wilders M, et al. Early detection and intervention using neutrophil gelatinase-associated lipocalin (NGAL) may improve renal outcome of acute contrast media induced nephropathy: A randomized controlled trial in patients undergoing intra-arterial angiography (ANTI-CIN Study. BMC Nephrol. 2011;12(1):39.

4. Yang Y, George KC, Luo R, Cheng Y, Shang W, Ge S, et al. Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Nephrol. 2018;19(1):374.

5. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013 Feb;6(1):37–43.

6. Li X, Liu C, Mao Z, Qi S, Song R, Zhou F. Brain Natriuretic Peptide for Predicting Contrast-Induced Acute Kidney Injury in Patients with Acute Coronary Syndrome Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis. J Interv Cardiol. 2020;2020.

7. Chen Z, Mao Q, Xiang L, Zhou D, Jiang Y, Zhao N, et al. Iodixanol-associated acute kidney injury and prognosis in patients undergoing elective percutaneous coronary intervention: a prospective, multicenter study. Eur Radiol. 2023;33(12):9444–54.

8. Yu S, Li Q, He Y, Jia C, Liang G, Lu H, et al. Comparison of cardiac biomarkers on risk assessment of contrast-associated acute kidney injury in patients undergoing cardiac catheterization: A multicenter retrospective study. Nephrology. 2023 Nov;28(11):588–96.

9. Lin K yang, Wu Z yong, You Z bin, Zheng W ping, Lin C jin, Jiang H, et al. Pre-Procedural N-Terminal Pro-B Type Natriuretic Peptide Predicts Contrast-Induced Acute Kidney Injury and Long-Term Outcome in Elderly Patients After Elective Percutaneous Coronary Intervention. Int Heart J. 2018;59(5):926–34.

10. Sůva M, Kala P, Poloczek M, Kaňovský J, Štípal R, Radvan M, et al. Contrast-induced acute kidney injury and its contemporary prevention. Vol. 9, Frontiers in Cardiovascular Medicine. 2022.

11. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018 Feb;378(7):603–14.

12. Wang K, Li H long, Chen L ling, Bei W jie, Lin K yang, Smyth B, et al. Association of N-terminal pro-brain natriuretic peptide with contrast-induced acute kidney injury and long-term mortality in patients with heart failure and mid-range ejection fraction: An observation study. Medicine (Baltimore). 2017;96(10).

13. Ying J, Wang J, Ying Z, Ran X, Zeng X, Chen D, et al. Exploring the relationship between post-contrast acute kidney injury and different baseline creatinine standards: A retrospective cohort study. Front Endocrinol (Lausanne). 2023;13(January):1–9.

14. Bartels ED, Brun GC, Gammeltoft A, Gjørup PA. Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand. 1954;150(4):297–302.

15. Ramachandran P, Jayakumar D. Contrast-induced Acute Kidney Injury. Indian J Crit care Med peer-reviewed, Off Publ Indian Soc Crit Care Med. 2020 Apr;24(Suppl 3):S122–5.

16. Qiu H, Zhu Y, Shen G, Wang Z, Li W. A Predictive Model for Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention in Elderly Patients with ST-Segment Elevation Myocardial Infarction. Clin Interv Aging. 2023;18:453–65.

17. Haq MFU, Yip CS, Arora P. The conundrum of contrast-induced acute kidney injury. J Thorac Dis. 2020 Apr;12(4):1721–7.

18. Silvain J, Nguyen LS, Spagnoli V, Kerneis M, Guedeney P, Vignolles N, et al. Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2018;104(9):767–72.

19. Shen G, He H, Zhang X, Wang L, Wang Z, Li F, et al. Predictive value of systemic immune-inflammation index combined with N-terminal pro-brain natriuretic peptide for contrast-induced acute kidney injury in patients with STEMI after primary PCI. Int Urol Nephrol. 2023;

20. International Society of Nephrology. Section 4: Contrast-induced AKI. Kidney Int Suppl. 2012;2(1):69–88.

21. van der Molen AJ, Dekkers IA, Bedioune I, Darmon-Kern E. A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2—intra-arterial administration. Eur Radiol. 2022;32(8):5546–58.

22. Helgason D, Long TE, Helgadottir S, Palsson R, Sigurdsson GH, Gudbjartsson T, et al. Acute kidney injury following coronary angiography: a nationwide study of incidence, risk factors and long-term outcomes. J Nephrol. 2018 Oct;31(5):721–30.

23. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-Induced Nephropathy: An “All or None” Phenomenon? Angiology. 2015 Jul;66(6):508–13.

24. Liu J, Xie Y, He F, Gao Z, Hao Y, Zu X, et al. Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial. Onorati F, editor. Biomed Res Int. 2016;2016:5985327.

25. Morcos R, Kucharik M, Bansal P, Al Taii H, Manam R, Casale J, et al. Contrast-Induced Acute Kidney Injury: Review and Practical Update. Clin Med Insights Cardiol. 2019 Jan;13:1179546819878680.

26. Kandarini Y, Wulandari P, Mahadita GW. Faktor resiko contrast induced nephropathy pada pasien yang menjalani prosedur coronary intervention. J Penyakit Dalam Udayana. 2021 Jun;5:20–5.

27. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. 2020 Oct;259:118379.

28. Ueda J, Nygren A, Sjöquist M, Jacobsson E, Ulfendahl HR, Araki Y. Iodine concentrations in the rat kidney measured by X-ray microanalysis. Comparison of concentrations and viscosities in the proximal tubules and renal pelvis after intravenous injections of contrast media. Acta Radiol. 1998 Jan;39(1):90–5.

29. Lancelot E, Idée JM, Couturier V, Vazin V, Corot C. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of Nephrotoxicity. J Appl Toxicol. 1999;19(5):341–6.

30. Ozkok S, Ozkok A. Contrast-induced acute kidney injury: A review of practical points. World J Nephrol. 2017 May;6(3):86–99.

31. Zager RA, Johnson ACM, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003 Jul;64(1):128–39.

32. Liss P, Nygren A, Erikson U, Ulfendahl HR. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int. 1998 Mar;53(3):698–702.

33. Liu Y hui, Liu Y, Zhou Y ling, Yu D qing, He P cheng, Xie N jin, et al. Association of N-terminal pro-B-type natriuretic peptide with contrast-induced nephropathy and long-term outcomes in patients with chronic kidney disease and relative preserved left ventricular function. Medicine (Baltimore). 2015 Apr;94(13):e358.

34. Wong PCY, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012 Jul;158(2):186–92.

35. Liu ZZ, Schmerbach K, Lu Y, Perlewitz A, Nikitina T, Cantow K, et al. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback. Am J Physiol Renal Physiol. 2014 Apr;306(8):F864-72.

36. Wijaya A, Atmadja B. Identifikasi Risiko dan Pencegahan Terhadap Nefropati Akibat Kontras. J Radiol Indones. 2016 Sep;2:52–8.

37. Song W, Zhang T, Pu J, Shen L, He B. Incidence and risk of developing contrast-induced acute kidney injury following intravascular contrast administration in elderly patients. Clin Interv Aging. 2014;9:85–93.

38. Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Vol. 3, Clinical journal of the American Society of Nephrology : CJASN. United States; 2008. p. 1242–3.

39. Luk L, Steinman J, Newhouse JH. Intravenous Contrast-Induced Nephropathy-The Rise and Fall of a Threatening Idea. Adv Chronic Kidney Dis. 2017 May;24(3):169–75.

40. Do C. Intravenous Contrast: Friend or Foe? A Review on Contrast-Induced Nephropathy. Adv Chronic Kidney Dis. 2017 May;24(3):147–9.

41. Schönenberger E, Martus P, Bosserdt M, Zimmermann E, Tauber R, Laule M, et al. Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial. Radiology. 2019 Sep;292(3):664–72.

42. Liu YH, Jiang L, Chen JY, Tan N, Liu Y, He PC. Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention? Int Urol Nephrol. 2016 Oct;48(10):1675–82.

43. Liu Y, He Y ting, Tan N, Chen J yan, Liu Y hui, Yang D hao, et al. Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography. J Am Heart Assoc. 2015 Apr;4(4).

44. Ni Z, Liang Y, Xie N, Liu J, Sun G, Chen S, et al. Simple pre-procedure risk stratification tool for contrast-induced nephropathy. J Thorac Dis. 2019 Apr;11(4):1597–610.

45. Mo H, Ye F, Chen D, Wang Q, Liu R, Zhang P, et al. A Predictive Model Based on a New CI-AKI Definition to Predict Contrast Induced Nephropathy in Patients With Coronary Artery Disease With Relatively Normal Renal Function. Front Cardiovasc Med. 2021;8:762576.

46. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct;44(7):1393–9.

47. Mehran R, Owen R, Chiarito M, Baber U, Sartori S, Cao D, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet (London, England). 2021 Nov;398(10315):1974–83.

48. Guo Y, Xu X, Xue Y, Zhao C, Zhang X, Cai H. Mehran 2 Contrast-Associated Acute Kidney Injury Risk Score: Is it Applicable to the Asian Percutaneous Coronary Intervention Population? Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2022;28:10760296221116352.

49. Zeng JL, Chen JH, Zhang LW, Chen LC, Liang WJ, You Z, et al. Lactate dehydrogenase-to-albumin ratio: A superior inflammatory marker for predicting contrast-associated acute kidney injury after percutaneous coronary intervention. Clin Cardiol. 2024;47(2).

50. Chang CF, Lin CC. Current concepts of contrast-induced nephropathy: A brief review. J Chinese Med Assoc [Internet]. 2013;76(12):673–81. Available from: http://dx.doi.org/10.1016/j.jcma.2013.08.011

51. Valle JA, McCoy LA, Maddox TM, Rumsfeld JS, Ho PM, Casserly IP, et al. Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 Apr;10(4):e004439.

52. Park J, Mebazaa A, Park JJ, Rhee TM, Park HA, Lee GY, et al. Incidence, Risk Factors and Prognosis of Contrast-Induced Acute Kidney Injury in Acute Heart Failure Patients Undergoing Coronary Angiography. Int J Hear Fail. 2019 Oct;1(1):72–85.

53. Ribitsch W, Horina JH, Quehenberger F, Rosenkranz AR, Schilcher G. Contrast Induced Acute Kidney Injury and its Impact on Mid-Term Kidney Function, Cardiovascular Events and Mortality. Sci Rep. 2019;9(1):16896.

54. Lee DJW, Aw TC. Natriuretic Peptides in Clinical Practice: A Current Review. J Immunol Sci. 2023;

55. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004 Mar;6(3):257–60.

56. Jehn S, Mahabadi AA, Pfohl C, Vogel L, Al-Rashid F, Luedike P, et al. BNP and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure. JACC Adv. 2023 Dec;2(10):100688.

57. Fu S, Ping P, Zhu Q, Ye P, Luo L. Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review. Front Physiol. 2018;9.

58. Çelik A, Kılıçaslan B, Temizhan A, Güvenç TS, Altay H, Çavuşoğlu Y, et al. How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction? Anatol J Cardiol. 2023 Jun;27(6):308–18.

59. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio. Am J Clin Pathol. 2010 Jan;133(1):14–23.

60. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci. 2019 Apr;20(8).

61. Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, et al. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019 Mar;73(11):1273–84.

62. Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44(3):303–8.

63. Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail. 2007;9(6–7):667–73.

64. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov;3(6):1644–51.

65. Fabbian F, De Giorgi A, Portaluppi F, Zuliani G. Relationship between N-terminal pro-B-type natriuretic peptide plasma levels and renal function evaluated with different formulae in older adult subjects admitted because of dyspnea. Gerontology. 2012;58(1):50–5.

66. Harrison TG, Shukalek CB, Hemmelgarn BR, Zarnke KB, Ronksley PE, Iragorri N, et al. Association of NT-proBNP and BNP With Future Clinical Outcomes in Patients With ESKD: A Systematic Review and Meta-analysis. Am J kidney Dis Off J Natl Kidney Found. 2020 Aug;76(2):233–47.

67. Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023 Nov;25(11):1891–8.

68. Chou YH, Chen YF, Pan SY, Huang TM, Yang FJ, Shen WC, et al. The role of brain natriuretic peptide in predicting renal outcome and fluid management in critically ill patients. J Formos Med Assoc. 2015;114(12):1187–96.

69. Abdelraouf IM, Badr SF, Ibrahim I, Elsokkary HM. Evaluation of Brain Natriuretic Peptide as a Predictor of Contrast Induced Acute Kidney Injury Post Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Int J Innov Res Med Sci. 2023 Sep;8(09 SE-Original Article):381–5.

70. Akgul O, Uyarel H, Pusuroglu H, Isiksacan N, Turen S, Erturk M, et al. High BNP level as risk factor for acute kidney injury and predictor of all-cause mortality in STEMI patients. Herz. 2014;39(4):507–14.

71. Semenov AG, Katrukha AG. Analytical Issues with Natriuretic Peptides - has this been Overly Simplified? EJIFCC. 2016 Aug;27(3):189–207.

72. Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006 Jul;451(2):160–6.

73. Nakagawa Y, Nishikimi T, Kuwahara K, Fujishima A, Oka S, Tsutamoto T, et al. MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts. J Am Heart Assoc. 2017 Feb;6(2).

74. Crimmins DL, Kao JLF. A glycosylated form of the human cardiac hormone pro B-type natriuretic peptide is an intrinsically unstructured monomeric protein. Arch Biochem Biophys. 2008 Jul;475(1):36–41.

75. Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloshchitsyna MN, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009 Mar;55(3):489–98.

76. Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R, Franzini M, et al. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim Acta. 2012 Dec;414:112–9.

77. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med. 2004;42(8):942–4.

78. Cauliez B, Guignery J, Marinier S, Mariau I, Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem. 2008 May;45(Pt 3):318–9.

79. Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12(1):2.

80. McMurray JJ V, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep;371(11):993–1004.

81. Luo M, Zhu Z, Zhang L, Zhang S, You Z, Chen H, et al. Predictive Value of N-Terminal Pro B-Type Natriuretic Peptide for Contrast-Induced Nephropathy Non-Recovery and Poor Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. Circ J. 2023 Jan;87(2):258–65.

82. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J kidney Dis Off J Natl Kidney Found. 2011 Nov;58(5):717–28.

83. Goussot S, Mousson C, Guenancia C, Stamboul K, Brunel P, Brunet D, et al. N-Terminal Fragment of Pro B-type Natriuretic Peptide as a Marker of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2015 Sep;116(6):865–71.

84. Li Y, Ma K, Shen G, Zheng D, Xuan Y, Li W. Impact of small and dense low-density lipoprotein (sd-LDL) on contrast-induced acute kidney injury in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int Urol Nephrol. 2021;53(12):2611–7.

85. Kurtul A, Duran M, Yarlioglues M, Murat SN, Demircelik MB, Ergun G, et al. Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Clin Cardiol. 2014 Aug;37(8):485–92.

86. Xu T, Lin M, Shen X, Wang M, Zhang W, Zhao L, et al. Association of the classification and severity of heart failure with the incidence of contrast-induced acute kidney injury. Sci Rep. 2021;11(1).

87. Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Card Fail. 2023;29(5):787–804.

88. Lydia A, Widiana IGR, Bandiara R, Afiatin, Ali Z, Nugroho P, et al. Nephrology in Indonesia BT - Nephrology Worldwide. In: Moura-Neto JA, Divino-Filho JC, Ronco C, editors. Cham: Springer International Publishing; 2021. p. 299–312.

89. Kementerian Kesehatan Republik Indonesia. Laporan Riskesdas 2018 Nasional.pdf. Lembaga Penerbit Balitbangkes. 2018.

90. Kementerian Kesehatan Republik Indonesia. Laporan Riskesdas 2013 Nasional. Lembaga Penerbit Balitbangkes. 2013.

91. Perhimpunan Nefrologi Indonesia. 13 th ANNUAL REPORT OF INDONESIAN RENAL REGISTRY 2020. 2023;1–37.

92. Maulana GH, Krisdinarti L, Hariawan H. The Differences of Average Level Serum N Terminal Prob-Type Natriuretic Peptide (NTPROBNP) in Hypertension Patients with and without Left Ventricular Hypertrophy At Cardiology Outpatients Dr. Sardjito General Hospital Yogyakarta. Acta Interna J Intern Med. 2015;(Vol 5, No 1 (2015): Acta Interna The Journal of Internal Medicine):1–8.

93. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord. 2020 Apr;20(1):163.

94. Simatupang LD, Susalit E, Wijaya IP. The Role of Hydration and N-Acetyl Cysteine Combination in 48Hours Contrast-Induced Nephropaty after Percutaneous CoronaryIntervention in Stage Three Chronic Kidney Disease Patients. J Penyakit Dalam Indones. 2016;(Vol. 3, No. 3).

95. Santosa Y, Harca AD, Yuwono A, Hermanto A, Oliver MS, Sukmadja E, et al. Is It Safe to Do Percutaneous Coronary Intervention in Moderate to Severe Chronic Kidney Disease Patients? A Prospective Cohort Study. Cureus. 2022 Oct;14(10):e30312.

96. Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev. 2016 May;37(2):85–98.

97. Prakash J, Singh TB, Ghosh B, Malhotra V, Rathore SS, Vohra R, et al. Changing epidemiology of community-acquired acute kidney injury in developing countries: analysis of 2405 cases in 26 years from eastern India. Clin Kidney J. 2013 Apr;6(2):150–5.

98. Lareyre F, Raffort J. Biomarkers of Contrast-Induced Nephropathy After Non-cardiac Vascular Procedures: An Under-explored Area. Vol. 73, Angiology. United States; 2022. p. 193–4.